Europe-Focused Cannabis Player Ready for Takeoff

We’re excited about the interview that we conducted with Mr. Daniel Cohen, the Chief Executive Officer of Aura Health Inc. (CA:BUZZ – $0.07 & US:LMLLF – $0.06). The Company is focused on building an international network of vertically-integrated cannabis assets with a clear focus on Europe.

Mr. Cohen first discusses Pharmadrug, a German importer and distributor of medical cannabis, of which Aura owns 80%. The schedule 1 narcotics distributor is already generating sales of medical cannabis to German pharmacies. Business is doing well. In fact, in July 2019 Pharmadrug generated a 300% revenue increase over the first four months of operations.

The CEO also describes Aura’s agreement to secure a 54% equity stake in HolyCanna, an Israeli-based company with a cannabis nursery and cultivation license. HolyCanna has plans to build a greenhouse for medical cannabis cultivation. The goal is to produce 2 million grams of cannabis per year and sell these domestically and abroad.

The interview also touches upon the Company’s second project in Israel, which is to build a retail consultancy clinic and pharmacy dispensary focused on cannabis. In order to do so, Aura signed an LOI with is CannabiSendak, a company that’s headed by Shlomi Sendak, a true icon for medical cannabis in Israel.

Mr. Cohen furthermore delivers plenty of valuable information about the massive potential for cannabis in Europe and Israel. He gives a thorough explanation about the current state of both markets and describes why the European cannabis space is ready to boom. Smallcaps recommendation: BUY.

Smallcaps Recommendation: Buy	Price Target: $0.21	Latest Company Report (pdf)
For important disclosures, please read our disclaimer.